Breaking Down Biologics in Atopic Dermatitis: Choosing the Right Path for Patients - Episode 11
Practical Considerations for Managing Atopic Dermatitis With Biologics
Panelists discuss how biologic therapy management requires strategic monitoring with initial assessment at 4 to 12 weeks, defining nonresponse at 12 to 16 weeks, addressing adherence before considering alternatives such as switching biologics with different mechanisms or transitioning to JAK inhibitors based on comorbidities, coverage, administration preferences, and safety considerations—emphasizing that the expanding therapeutic landscape enables personalized approaches that have transformed expectations for moderate to severe atopic dermatitis.
Video content above is prompted by the following:
- When you start a patient on a biologic, how often are you monitoring the patient’s treatment regimen for effectiveness?
- When do you consider a patient a nonresponder to their current treatment?
- If a patient is not responding to their current biologic or discontinues it for any reason, what would be your next approach to treatment?
- Do you have any practice pearls for adherence for potential nonresponders?
- What impact would switching to another systemic therapy with a different mechanism of action have on the patient?
- How would you decide whether to switch to another biologic or switch to an oral JAK inhibitor?
- What closing thoughts do you have on the use of biologics in moderate to severe atopic dermatitis?
